Compounds > ticlopidine
Page last updated: 2024-11-05

ticlopidine and Angina Pectoris, Stable

ticlopidine has been researched along with Angina Pectoris, Stable in 25 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research Excerpts

ExcerptRelevanceReference
"Pre-treatment of clopidogrel 600 mg is better than 300 mg loading for reducing periprocedural myocardial infarction (PMI)."9.34Prospective partially randomized comparison of clopidogrel loading versus maintenance dosing to prevent periprocedural myocardial infarction after stenting for stable angina pectoris: Results from the "Method of Clopidogrel Pre-treatment Undergoing Conven ( Ahn, CM; Ahn, KJ; Choi, JW; Hong, SJ; Joo, HJ; Kim, JS; Lim, DS; Park, JH; Yu, CW, 2020)
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding."9.22Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
"Literature archives (Pubmed, EMBASE, Cochrane) and main scientific sessions abstracts were scanned for randomized trials comparing new ADP antagonists with clopidogrel in patients with acute coronary syndromes or stable angina."8.90Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. ( Barbieri, L; Cassetti, E; De Luca, G; Galasso, G; Marino, P; Piccolo, R; Schaffer, A; Sinigaglia, F; Verdoia, M, 2014)
"To investigate whether an intensified antiplatelet regimen could improve prognosis in stable or non-ST elevation in acute coronary syndrome (ACS) patients exhibiting high on-treatment platelet reactivity (HTPR) on clopidogrel and treated with percutaneous coronary intervention (PCI)."7.81Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. ( Clemmensen, P; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Kollslid, R; Lønborg, JT; Paarup Dridi, N; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K, 2015)
"Obesity is a cluster of medical conditions affecting several pathophysiological processes, including platelet (PLT) function."5.42Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention. ( Gąsior, Z; Haberka, M; Kyrcz-Krzemień, S; Lasota, B; Mizia-Stec, K, 2015)
"Pre-treatment of clopidogrel 600 mg is better than 300 mg loading for reducing periprocedural myocardial infarction (PMI)."5.34Prospective partially randomized comparison of clopidogrel loading versus maintenance dosing to prevent periprocedural myocardial infarction after stenting for stable angina pectoris: Results from the "Method of Clopidogrel Pre-treatment Undergoing Conven ( Ahn, CM; Ahn, KJ; Choi, JW; Hong, SJ; Joo, HJ; Kim, JS; Lim, DS; Park, JH; Yu, CW, 2020)
"Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone."5.24Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). ( Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW, 2017)
"The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding."5.22Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016)
" Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS)."5.16Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Schechter, CB; Viswanathan, GN; Zaman, AG, 2012)
"Literature archives (Pubmed, EMBASE, Cochrane) and main scientific sessions abstracts were scanned for randomized trials comparing new ADP antagonists with clopidogrel in patients with acute coronary syndromes or stable angina."4.90Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. ( Barbieri, L; Cassetti, E; De Luca, G; Galasso, G; Marino, P; Piccolo, R; Schaffer, A; Sinigaglia, F; Verdoia, M, 2014)
"To investigate whether an intensified antiplatelet regimen could improve prognosis in stable or non-ST elevation in acute coronary syndrome (ACS) patients exhibiting high on-treatment platelet reactivity (HTPR) on clopidogrel and treated with percutaneous coronary intervention (PCI)."3.81Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. ( Clemmensen, P; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Kollslid, R; Lønborg, JT; Paarup Dridi, N; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K, 2015)
"Pantoprazole treatment does not impair the efficacy of dual antiplatelet therapy in patients with SAP after PCI."2.77Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. ( Chmiel, A; Gąsior, Z; Gieszczyk, K; Haberka, M; Kunecki, M; Kyrcz-Krzemień, S; Lasota, B; Mizia, M; Mizia-Stec, K; Najda, J, 2012)
"Obesity is a cluster of medical conditions affecting several pathophysiological processes, including platelet (PLT) function."1.42Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention. ( Gąsior, Z; Haberka, M; Kyrcz-Krzemień, S; Lasota, B; Mizia-Stec, K, 2015)

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's24 (96.00)24.3611
2020's1 (4.00)2.80

Authors

AuthorsStudies
Park, JH1
Kim, JS1
Ahn, CM1
Hong, SJ1
Ahn, KJ1
Choi, JW1
Joo, HJ1
Yu, CW1
Lim, DS1
Jiang, Z1
Wu, H1
Duan, Z1
Wang, Z1
Hu, K1
Ye, F1
Zhang, Z1
Phankingthongkum, R1
Panchavinnin, P1
Chinthammitr, Y1
Tresukosol, D1
Chotinaiwattarakul, C1
Tungsubutra, W1
Wongpraparut, N1
Kitrattana, B1
Leewanun, P1
Kim, HS1
Chang, K1
Koh, YS1
Park, MW1
Choi, YS1
Park, CS1
Oh, M1
Kim, EY1
Shon, JH1
Shin, JG1
Seung, KB1
Verdoia, M1
Schaffer, A1
Barbieri, L1
Cassetti, E1
Piccolo, R1
Galasso, G1
Marino, P1
Sinigaglia, F1
De Luca, G1
Woo, JS1
Kim, W1
Jang, HH1
Kim, JB1
Kim, WS1
Kim, KS1
Mizia-Stec, K3
Mizia, M2
Haberka, M3
Lasota, B3
Gieszczyk-Strózik, K1
Chmiel, A2
Najda, J2
Gąsior, Z3
Kyrcz-Krzemień, S3
Legrand, V2
Cuisset, T1
Chenu, P2
Vrolix, M2
Martinez, C1
Dens, J1
Gach, O1
Boland, J1
Claeys, MJ1
Magne, J2
Barbato, E2
Wijns, W2
Arima, Y1
Hokimoto, S1
Akasaka, T1
Mizobe, K1
Kaikita, K1
Oniki, K1
Nakagawa, K1
Ogawa, H1
Paarup Dridi, N1
Johansson, PI1
Lønborg, JT1
Clemmensen, P1
Radu, MD1
Qayyum, A1
Pedersen, F1
Kollslid, R1
Helqvist, S1
Saunamäki, K2
Kelbæk, H2
Jørgensen, E1
Engstrøm, T1
Holmvang, L1
Rossini, R1
Musumeci, G1
Capodanno, D1
Lettieri, C1
Limbruno, U1
Tarantini, G1
Russo, N1
Calabria, P1
Romano, M1
Inashvili, A1
Sirbu, V1
Guagliumi, G1
Valsecchi, O1
Senni, M1
Gavazzi, A1
Angiolillo, DJ1
Kristensen, SL1
Galløe, AM1
Thuesen, L1
Thayssen, P1
Havndrup, O1
Hansen, PR1
Bligaard, N1
Junker, A1
Aarøe, J1
Abildgaard, U1
Jeppesen, JL1
Konishi, A1
Shinke, T1
Otake, H1
Takaya, T1
Osue, T1
Kinutani, H1
Kuroda, M1
Takahashi, H1
Terashita, D1
Hirata, K1
Ako, J1
Morino, Y1
Okuizumi, K1
Usami, M1
Nakamura, M2
Legrand, D1
Abtan, J1
Steg, PG1
Stone, GW1
Mahaffey, KW1
Gibson, CM1
Hamm, CW1
Price, MJ1
Abnousi, F1
Prats, J1
Deliargyris, EN1
White, HD1
Harrington, RA1
Bhatt, DL1
Stefanescu Schmidt, AC1
Kereiakes, DJ1
Cutlip, DE1
Yeh, RW1
D'Agostino, RB1
Massaro, JM1
Hsieh, WH1
Mauri, L1
Aradi, D1
Rideg, O1
Vorobcsuk, A1
Magyarlaki, T1
Magyari, B1
Kónyi, A1
Pintér, T1
Horváth, IG1
Komócsi, A1
Motoda, C1
Ueda, H1
Hayashi, Y1
Toyofuku, M1
Okimoto, T1
Otsuka, M1
Tamekiyo, H1
Kawase, T1
Kihara, Y1
Volpi, E1
Giusti, L1
Ciregia, F1
Da Valle, Y1
Giannaccini, G1
Berti, S1
Clerico, A1
Lucacchini, A1
Kunecki, M1
Gieszczyk, K1
Isshiki, T1
Kimura, T1
Ueno, T1
Igarashi, K1
Yokoi, H1
Kobayashi, M1
Ikari, Y1
Viswanathan, GN1
Marshall, SM1
Schechter, CB1
Balasubramaniam, K1
Badimon, JJ1
Zaman, AG1
Shetty, RK1
Madken, M1
Naha, K1
Vivek, G1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
CathOlic Medical Center percutAneous Coronary inTervention Registry (COACT)[NCT01239914]11,719 participants (Actual)Observational2005-01-31Completed
Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835]1,492 participants (Anticipated)Observational [Patient Registry]2019-08-01Recruiting
MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651]Phase 2140 participants (Anticipated)Interventional2019-06-01Not yet recruiting
A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571]Phase 311,145 participants (Actual)Interventional2010-09-30Completed
A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938]Phase 425,682 participants (Actual)Interventional2009-10-31Completed
150 mg Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity After Elective Percutaneous Coronary Intervention[NCT00638326]Phase 3500 participants (Anticipated)Interventional2008-03-31Terminated (stopped due to Greater differences between randomized patients than previously anticipated)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

The Composite Incidence of All-cause Mortality, Myocardial Infarction (MI), Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)

Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization

Interventionparticipants (Number)
Cangrelor Treatment Arm257
Clopidogrel Treatment Arm322

Incidence of Major/Minor Non-coronary Artery Bypass Graft (CABG)-Related Hemorrhage by Clinical Relevant Criteria - GUSTO Severe/Life-threatening, Moderate and Mild

GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
GUSTO severe/life threateningGUSTO moderateGUSTO severe or moderateTIMI majorTIMI minorTIMI major or minorAny blood transfusion
Cangrelor Treatment Arm92231591425
Clopidogrel Treatment Arm6131953816

Individual Incidence of Stent Thrombosis (ST), Death, Myocardial Infarction (MI) and Ischemia-driven Revascularization (IDR)

CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization

,
Interventionparticipants (Number)
Stent ThrombosisDeathMI (myocardial infarction)IDR (ischemia-driven revascularization)
Cangrelor Treatment Arm461820728
Clopidogrel Treatment Arm741825538

Definite or Probable Stent Thrombosis (ST) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Interventionpercentage of patients (Number)
Propensity-matched DES1.70
Propensity-matched BMS2.61

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT0.50
BMS 12-month DAPT1.11

Definite or Probable Stent Thrombosis (ST) - Randomized BMS ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT0.50
BMS 12-month DAPT1.11

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT0.69
DES 12-month DAPT1.45

Definite or Probable Stent Thrombosis (ST) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT0.40
DES 12-month DAPT1.35

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (Number)
BMS 30-month DAPT2.03
BMS 12-month DAPT0.90

GUSTO Severe or Moderate Bleeding - Randomized BMS ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (Number)
BMS 30-month DAPT2.09
BMS 12-month DAPT1.05

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (Number)
DES 30-month DAPT2.74
DES 12-month DAPT1.88

GUSTO Severe or Moderate Bleeding - Randomized DES ITT

The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (Number)
DES 30-month DAPT2.53
DES 12-month DAPT1.57

MACCE (Death, Myocardial Infarction or Stroke) - Propensity Matched DES vs. BMS

Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)

Interventionpercentage of patients (Number)
Propensity-matched DES11.37
Propensity-matched BMS13.24

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT4.04
BMS 12-month DAPT4.69

MACCE (Death, Myocardial Infarction or Stroke) - Randomized BMS ITT

(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
BMS 30-month DAPT4.68
BMS 12-month DAPT5.48

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT5.62
DES 12-month DAPT6.49

MACCE (Death, Myocardial Infarction or Stroke) - Randomized DES ITT

The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)

Interventionpercentage of patients (KM estimate) (Number)
DES 30-month DAPT4.34
DES 12-month DAPT5.92

Reviews

1 review available for ticlopidine and Angina Pectoris, Stable

ArticleYear
Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.
    Journal of cardiovascular pharmacology, 2014, Volume: 63, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angina, Stable; Case Management; Clopidogrel; Endpoi

2014

Trials

13 trials available for ticlopidine and Angina Pectoris, Stable

ArticleYear
Prospective partially randomized comparison of clopidogrel loading versus maintenance dosing to prevent periprocedural myocardial infarction after stenting for stable angina pectoris: Results from the "Method of Clopidogrel Pre-treatment Undergoing Conven
    International journal of clinical pharmacology and therapeutics, 2020, Volume: 58, Issue:10

    Topics: Angina, Stable; Clopidogrel; Coronary Angiography; Humans; Myocardial Infarction; Percutaneous Coron

2020
CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.
    Circulation. Cardiovascular genetics, 2013, Volume: 6, Issue:5

    Topics: Adult; Aged; Alleles; Angina, Stable; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 C

2013
N-3 polyunsaturated fatty acids do not influence the efficacy of dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
    Cardiology journal, 2013, Volume: 20, Issue:5

    Topics: Aged; Angina, Stable; Aspirin; Blood Platelets; Clopidogrel; Docosahexaenoic Acids; Drug Combination

2013
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:2

    Topics: Aged; Angina, Stable; Aspirin; Belgium; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coron

2014
The STIB score: a simple clinical test to predict clopidogrel resistance.
    Acta cardiologica, 2015, Volume: 70, Issue:5

    Topics: Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Belgium; Biomarkers; Blood Platelets; Body Mas

2015
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    JACC. Cardiovascular interventions, 2016, 09-26, Volume: 9, Issue:18

    Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clo

2016
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
    Circulation, 2017, May-02, Volume: 135, Issue:18

    Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Bli

2017
Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity.
    European journal of clinical investigation, 2012, Volume: 42, Issue:4

    Topics: Aged; Angina, Stable; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relations

2012
Impact of platelet reactivity to adenosine diphosphate before implantation of drug-eluting stents on subsequent adverse cardiac events in patients with stable angina.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:3

    Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angina, Stable; Aspirin; Drug-Eluting Stents; Female

2012
Platelet proteome and clopidogrel response in patients with stable angina undergoing percutaneous coronary intervention.
    Clinical biochemistry, 2012, Volume: 45, Issue:10-11

    Topics: Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Blood Platelets; Blotting, Western; Clopidogre

2012
Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention.
    Pharmacological reports : PR, 2012, Volume: 64, Issue:2

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Cl

2012
Clopidogrel trial in patients with elective percutaneous coronary intervention for stable angina and old myocardial infarction (CLEAN).
    International heart journal, 2012, Volume: 53, Issue:2

    Topics: Adult; Aged; Angina, Stable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality

2012
Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina.
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:5

    Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Fema

2012

Other Studies

11 other studies available for ticlopidine and Angina Pectoris, Stable

ArticleYear
Proton-pump inhibitors can decrease gastrointestinal bleeding after percutaneous coronary intervention.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:6

    Topics: Acute Coronary Syndrome; Age Factors; Aged; Alcohol Drinking; Angina, Stable; Aspirin; Case-Control

2013
High on-clopidogrel treatment platelet reactivity in Thai patients with chronic stable angina scheduled for percutaneous coronary intervention.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2013, Volume: 96, Issue:5

    Topics: Aged; Angina, Stable; Clopidogrel; Coronary Angiography; Coronary Restenosis; Female; Humans; Male;

2013
Effect of platelet reactivity, endothelial function, and inflammatory status on outcomes in patients with stable angina pectoris on clopidogrel therapy.
    The American journal of cardiology, 2014, Mar-01, Volume: 113, Issue:5

    Topics: Aged; Angina, Stable; Blood Platelets; Brachial Artery; Cell Count; Clopidogrel; Endothelium, Vascul

2014
Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
    Journal of cardiology, 2015, Volume: 65, Issue:6

    Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Stable; Aspirin; Blood Platelets; Clopidogrel; Cytoc

2015
Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.
    Platelets, 2015, Volume: 26, Issue:6

    Topics: Acute Coronary Syndrome; Angina, Stable; Clopidogrel; Female; Humans; Male; Percutaneous Coronary In

2015
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:2

    Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten

2015
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:2

    Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten

2015
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:2

    Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten

2015
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
    Thrombosis and haemostasis, 2015, Volume: 113, Issue:2

    Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten

2015
Stent thrombosis is the primary cause of ST-segment elevation myocardial infarction following coronary stent implantation: a five year follow-up of the SORT OUT II study.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: Aged; Angina, Stable; Clopidogrel; Cohort Studies; Drug-Eluting Stents; Female; Follow-Up Studies; H

2014
Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention.
    Polskie Archiwum Medycyny Wewnetrznej, 2015, Volume: 125, Issue:9

    Topics: Aged; Angina, Stable; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Obesity; Percutaneous

2015
Impact of residual platelet reactivity under clopidogrel treatment for lesions and the clinical outcome after drug-eluting stent implantation in patients with hemodialysis.
    Journal of cardiology, 2016, Volume: 67, Issue:6

    Topics: Aged; Angina, Stable; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Drug Therapy, Com

2016
Japanese postmarketing surveillance of clopidogrel in patients with non-ST-segment elevation acute coronary syndrome, stable angina, old myocardial infarction, and ST-segment elevation myocardial infarction after percutaneous coronary intervention in a re
    Cardiovascular intervention and therapeutics, 2016, Volume: 31, Issue:2

    Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Stable; Asian People; Clopidogrel; Female;

2016
Leucocytoclastic vasculitis as a late complication of clopidogrel therapy.
    BMJ case reports, 2013, Jan-17, Volume: 2013

    Topics: Angina, Stable; Biopsy; Clopidogrel; Female; Follow-Up Studies; Humans; Middle Aged; Purinergic P2Y

2013